Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
therapeutic tumor-infiltrating lymphocytes (St. Luke's Medical Center)
- Development stage
- Discontinued
- Lead developer
- St. Luke's Medical Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Therapeutic tumor-infiltrating lymphocytes (TILs) developed at St. Luke's Medical Center represent an autologous adoptive cell therapy investigated for the treatment of advanced melanoma. The therapeutic process involves the surgical resection of a patient's tumor to isolate naturally occurring T cells that have already infiltrated the malignancy. These cells are then expanded to large populations ex vivo using high-dose interleukin-2 (IL-2). Once expanded, the TILs are re-infused into the patient, typically following a lymphodepleting conditioning regimen (such as cyclophosphamide) and accompanied by systemic IL-2 to support cell survival and indomethacin to inhibit immunosuppressive prostaglandins. The infused TILs are intended to recognize and mediate the destruction of melanoma cells through their endogenous T-cell receptors, providing a polyclonal immune response against various tumor-associated antigens.
- Other names
- TIL therapytumor-infiltrating lymphocytestherapeutic tumor infiltrating lymphocytes
02
Targets
pMHC (Patient-specific tumor-associated antigen and neoantigen-derived peptide–major histocompatibility complex)
Beyond the preview
Go deeper on therapeutic tumor-infiltrating lymphocytes (St. Luke's Medical Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on therapeutic tumor-infiltrating lymphocytes (St. Luke's Medical Center).